1                                              Nedocromil (10 nM) also inhibited (40-60%) the release o

2 n pre-treatment with cromoglycate (10 nM) or nedocromil (10 nM), as well as dexamethasone (2 nM) and

3 cromones' (di-sodium cromoglycate and sodium nedocromil) are used to treat allergy and asthma, their

4 as 0.2 cm lower (95% CI, -0.9 to 0.5) in the nedocromil group than in the placebo group (P=0.61).

5  further investigated whether budesonide and nedocromil modified pollution effects.

6 d to receive 400 mug of budesonide, 16 mg of nedocromil, or placebo daily for 4 to 6 years.

7 was randomly assigned to receive budesonide, nedocromil, or placebo for 4-6 years, we determined the

8  compared with those treated with placebo or nedocromil (P < 0.001).

9 ve response to both budesonide (P = .02) and nedocromil (P = .01) compared with placebo, whereas the

10 l responses to both budesonide (P = .12) and nedocromil (P = .56) compared with placebo.

11 d antiallergic ligands cromolyn disodium and nedocromil sodium, we identified the related compounds l

12 he placebo ["discovery"] and P < 0.05 in the nedocromil treatment ["replication"] group).